MDA-MB-468 Cell Lysate: sc-2282

MDA-MB-468 cell lysate is derived from a human breast adenocarcinoma cell line, extensively used in cancer research to investigate the biology of triple-negative breast cancer (TNBC). This lysate provides a comprehensive resource for analyzing protein expression and post-translational modifications associated with aggressive cancer phenotypes. Researchers utilize MDA-MB-468 lysate to study mechanisms of oncogenesis and tumor progression, focusing on the aberrant signaling pathways characteristic of TNBC, such as those involving EGFR and p53. The cell line is particularly noted for its high expression of the epidermal growth factor receptor (EGFR), making the lysate useful for examining signal transduction pathways that lead to uncontrolled cell proliferation and survival. In addition, this lysate facilitates the study of cellular responses to environmental stressors and chemotherapeutic agents, providing insights into the mechanisms of drug resistance and cell death. By conducting proteomic profiling and biochemical assays using this lysate, scientists can uncover potential biomarkers for cancer diagnosis and explore novel targets for cancer treatment, strictly within a research context. This enables a deeper understanding of the molecular underpinnings of TNBC and aids in the development of more effective research tools.

MDA-MB-468 Cell Lysate References:

1. The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells.  |  Chen, KY., et al. 2004. Oncogene. 23: 1854-62. PMID: 14676838
2. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.  |  Hu, M., et al. 2006. Bioconjug Chem. 17: 1280-7. PMID: 16984139
3. Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets.  |  Kulasingam, V. and Diamandis, EP. 2007. Mol Cell Proteomics. 6: 1997-2011. PMID: 17656355
4. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.  |  Oliveras-Ferraros, C., et al. 2008. Int J Oncol. 33: 1165-76. PMID: 19020749
5. Soluble L1CAM promotes breast cancer cell adhesion and migration in vitro, but not invasion.  |  Li, Y. and Galileo, DS. 2010. Cancer Cell Int. 10: 34. PMID: 20840789
6. Cosmomycin C inhibits signal transducer and activator of transcription 3 (STAT3) pathways in MDA-MB-468 breast cancer cell.  |  Kim, J., et al. 2011. Bioorg Med Chem. 19: 7582-9. PMID: 22071520
7. Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells.  |  Arabsolghar, R., et al. 2013. Mol Biol Rep. 40: 2617-25. PMID: 23242655
8. Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells.  |  Chen, L. and Bourguignon, LY. 2014. Mol Cancer. 13: 52. PMID: 24606718
9. TP53 Binding to BRCA1 and RAD51 in MCF7 and MDA-MB-468 Breast Cancer Cell Lines In vivo and In vitro.  |  Rasti, M. and Azimi, T. 2015. Avicenna J Med Biotechnol. 7: 76-9. PMID: 26140185
10. Targeted Delivery of an Activatable Fluorescent Probe for the Detection of Furin Activity in Living Cells.  |  Zhao, X., et al. 2018. Chembiochem. 19: 1060-1065. PMID: 29465834
11. Overexpressing modified human TRβ1 suppresses the proliferation of breast cancer MDA-MB-468 cells.  |  Peng, X., et al. 2018. Oncol Lett. 16: 785-792. PMID: 29963146
12. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.  |  McKnight, BN., et al. 2020. Breast Cancer Res. 22: 37. PMID: 32295603
13. Vinculin is associated with the E-cadherin adhesion complex.  |  Hazan, RB., et al. 1997. J Biol Chem. 272: 32448-53. PMID: 9405455